Statement of Changes in Beneficial Ownership (4)
June 26 2020 - 4:24PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Arjona Ferreira Juan Camilo |
2. Issuer Name and Ticker or Trading Symbol
Myovant Sciences Ltd.
[
MYOV
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Medical Officer |
|
(Last)
(First)
(Middle)
C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/24/2020 |
|
(Street)
BRISBANE, CA 94005
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 6/24/2020 | | M | | 10946 | A | $7.78 | 156061 | D | |
| Common Stock | 6/24/2020 | | M | | 6500 | A | $7.78 | 162561 | D | |
| Common Stock | 6/24/2020 | | S | | 17446 (1) | D | $20.00 | 145115 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | $7.78 | 6/24/2020 | | M | | | 10946 | (2) | 8/14/2027 | Common Stock | 10946 | $0.00 | 245000 | D | |
| Stock Option (Right to Buy) | $7.78 | 6/24/2020 | | M | | | 6500 | (3) | 4/15/2028 | Common Stock | 6500 | $0.00 | 80550 | D | |
| Explanation of Responses: |
| (1) | Shares sold pursuant to a 10b5-1 trading plan. |
| (2) | 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Of the vested portion of this option, 130,000 shares cannot be exercised for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. |
| (3) | 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Of the vested portion of this option, 27,204 shares cannot be exercised for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Arjona Ferreira Juan Camilo
C/O MYOVANT SCIENCES INC.
2000 SIERRA POINT PARKWAY, 9TH FLOOR
BRISBANE, CA 94005 |
|
| Chief Medical Officer |
|
Signatures
|
| /s/ Matthew Lang, Attorney-in-fact | | 6/26/2020 |
| **Signature of Reporting Person | Date |
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Apr 2023 to Apr 2024
